Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.36
At close: Nov 11 EDT
$10.36
N/A
Pre-Market: 4:00 PM EDT
Comments
Loading...
Day One Biopharmaceutical Analyst Ratings and Price Targets | NASDAQ:DAWN | Benzinga
Day One Biopharmaceuticals Inc has a consensus price target of $29.82 based on the ratings of 12 analysts. The high is $40 issued by Piper Sandler on July 8, 2024. The low is $16 issued by Needham on August 6, 2025. The 3 most-recent analyst ratings were released by JP Morgan, Piper Sandler, and HC Wainwright & Co. on November 7, 2025, November 5, 2025, and August 6, 2025, respectively. With an average price target of $26 between JP Morgan, Piper Sandler, and HC Wainwright & Co., there's an implied 150.97% upside for Day One Biopharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Piper Sandler
HC Wainwright & Co.
Needham
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Day One Biopharmaceutical
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/07/2025 | 160.62% | JP Morgan | $26 → $27 | Maintains | Overweight | |||
11/05/2025 | 150.97% | Piper Sandler | $25 → $26 | Maintains | Overweight | |||
08/06/2025 | 141.31% | HC Wainwright & Co. | $36 → $25 | Maintains | Buy | |||
08/06/2025 | 54.44% | Needham | $18 → $16 | Maintains | Buy | |||
05/07/2025 | 160.62% | Needham | $30 → $27 | Maintains | Buy | |||
04/03/2025 | 247.49% | HC Wainwright & Co. | $36 → $36 | Reiterates | Buy → Buy | |||
03/25/2025 | 160.62% | Goldman Sachs | $39 → $27 | Maintains | Buy | |||
03/05/2025 | 228.19% | JP Morgan | $39 → $34 | Maintains | Overweight | |||
02/26/2025 | 208.88% | Wedbush | $32 → $32 | Reiterates | Outperform → Outperform | |||
02/26/2025 | 247.49% | HC Wainwright & Co. | $40 → $36 | Maintains | Buy | |||
02/26/2025 | 208.88% | Needham | $32 → $32 | Reiterates | Buy → Buy | |||
02/10/2025 | 315.06% | Goldman Sachs | $48 → $43 | Maintains | Buy | |||
01/13/2025 | 218.53% | Needham | $33 → $33 | Reiterates | Buy → Buy | |||
01/07/2025 | 141.31% | B of A Securities | $28 → $25 | Maintains | Buy | |||
12/17/2024 | 228.19% | Jones Trading | — | $39 → $34 | Maintains | Buy | ||
10/31/2024 | 286.1% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
10/31/2024 | 218.53% | Needham | $33 → $33 | Reiterates | Buy → Buy | |||
10/09/2024 | 218.53% | Needham | $32 → $33 | Maintains | Buy | |||
08/06/2024 | 247.49% | JP Morgan | $38 → $36 | Maintains | Overweight | |||
08/01/2024 | 286.1% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
08/01/2024 | 131.66% | B of A Securities | $11 → $24 | Upgrade | Underperform → Buy | |||
07/31/2024 | 208.88% | Needham | $33 → $32 | Maintains | Buy | |||
07/30/2024 | 218.53% | Needham | $33 → $33 | Reiterates | Buy → Buy | |||
07/26/2024 | 286.1% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
07/08/2024 | 286.1% | Piper Sandler | $40 → $40 | Maintains | Overweight | |||
06/20/2024 | 286.1% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
06/19/2024 | 218.53% | Needham | $33 → $33 | Reiterates | Buy → Buy | |||
05/07/2024 | 218.53% | Needham | $33 → $33 | Reiterates | Buy → Buy | |||
05/07/2024 | 286.1% | HC Wainwright & Co. | $50 → $40 | Maintains | Buy | |||
04/25/2024 | 218.53% | Needham | $33 → $33 | Reiterates | Buy → Buy | |||
04/24/2024 | 382.63% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/24/2024 | 218.53% | Needham | $30 → $33 | Maintains | Buy | |||
04/22/2024 | 247.49% | JP Morgan | $32 → $36 | Maintains | Overweight | |||
03/26/2024 | 286.1% | Piper Sandler | $40 → $40 | Maintains | Overweight | |||
02/28/2024 | 286.1% | Piper Sandler | $45 → $40 | Maintains | Overweight | |||
02/27/2024 | 324.71% | Goldman Sachs | $50 → $44 | Maintains | Buy | |||
02/27/2024 | — | Oppenheimer | — | Reiterates | Perform → Perform | |||
11/07/2023 | 237.84% | Wedbush | $39 → $35 | Maintains | Outperform | |||
11/07/2023 | 228.19% | Needham | → $34 | Reiterates | Buy → Buy | |||
09/12/2023 | 266.8% | Wedbush | → $38 | Reiterates | Outperform → Outperform | |||
09/12/2023 | 228.19% | Needham | → $34 | Reiterates | Buy → Buy | |||
08/08/2023 | 228.19% | Needham | → $34 | Reiterates | → Buy | |||
08/08/2023 | 421.24% | Goldman Sachs | $63 → $54 | Maintains | Buy | |||
08/08/2023 | 382.63% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy | |||
06/05/2023 | 266.8% | Wedbush | → $38 | Reiterates | Outperform → Outperform | |||
06/05/2023 | 286.1% | Needham | → $40 | Reiterates | Buy → Buy | |||
06/05/2023 | 382.63% | HC Wainwright & Co. | $45 → $50 | Maintains | Buy | |||
05/18/2023 | 334.36% | HC Wainwright & Co. | → $45 | Reiterates | Buy → Buy | |||
05/08/2023 | 286.1% | Needham | $44 → $40 | Maintains | Buy | |||
05/02/2023 | 324.71% | Needham | → $44 | Reiterates | → Buy | |||
04/25/2023 | -13.13% | B of A Securities | $34 → $9 | Downgrade | Buy → Underperform | |||
04/05/2023 | 324.71% | Needham | $48 → $44 | Maintains | Buy | |||
03/07/2023 | 363.32% | Needham | → $48 | Reiterates | → Buy | |||
03/07/2023 | 334.36% | HC Wainwright & Co. | → $45 | Reiterates | → Buy | |||
02/08/2023 | 286.1% | Capital One | → $40 | Initiates | → Overweight | |||
02/03/2023 | — | Oppenheimer | — | Initiates | → Perform | |||
01/09/2023 | 498.46% | Goldman Sachs | $45 → $62 | Maintains | Buy | |||
01/09/2023 | 334.36% | Piper Sandler | $40 → $45 | Maintains | Overweight | |||
01/09/2023 | 334.36% | HC Wainwright & Co. | $35 → $45 | Maintains | Buy | |||
12/15/2022 | 237.84% | HC Wainwright & Co. | → $35 | Initiates | → Buy | |||
12/14/2022 | 286.1% | Needham | → $40 | Initiates | → Buy | |||
12/05/2022 | 334.36% | Goldman Sachs | → $45 | Initiates | → Buy | |||
12/01/2022 | 228.19% | B of A Securities | → $34 | Initiates | → Buy |
FAQ
What is the target price for Day One Biopharmaceutical (DAWN) stock?
The latest price target for Day One Biopharmaceutical (NASDAQ:DAWN) was reported by JP Morgan on November 7, 2025. The analyst firm set a price target for $27.00 expecting DAWN to rise to within 12 months (a possible 160.62% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?
The latest analyst rating for Day One Biopharmaceutical (NASDAQ:DAWN) was provided by JP Morgan, and Day One Biopharmaceutical maintained their overweight rating.
When was the last upgrade for Day One Biopharmaceutical (DAWN)?
The last upgrade for Day One Biopharmaceuticals Inc happened on August 1, 2024 when B of A Securities raised their price target to $24. B of A Securities previously had an underperform for Day One Biopharmaceuticals Inc.
When was the last downgrade for Day One Biopharmaceutical (DAWN)?
The last downgrade for Day One Biopharmaceuticals Inc happened on April 25, 2023 when B of A Securities changed their price target from $34 to $9 for Day One Biopharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on November 7, 2025 so you should expect the next rating to be made available sometime around November 7, 2026.
Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?
While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a maintained with a price target of $26.00 to $27.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $10.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
